It is also in clinical study
for tardive dyskinesia. Since it is FDA approved
for other purposes I was allowed to try it (with mixed results) but it is part of a new class of antipsychotics in development, the 5-HT3 receptor antagonists that are being researched as adjuncts (in addition to standard antipsychotics) treatments for schizophrenia.